The Japanese team has developed an "AI drug-making" system that can significantly reduce the cost of developing new drugs. January 31, 2019 Source: Ministry of Science and Technology According to "West Japan News", Kyushu Institute of Technology has developed an "AI drug-making" system. The system is able to predict whether existing drugs for a certain disease are effective against other diseases based on the analysis of long-term accumulated medical data using artificial intelligence (AI). The researchers noted that different types of protein variation exist between different diseases, so AI is used to compare various types of protein variation, and then the corresponding alternative drugs are matched according to the similarity of the protein variation types. The specific practice of this "AI drug" is to first analyze the protein variation in about 1,300 diseases and the various components of about 8,000 drugs, and find out a group of diseases with similar protein variations. , correlate them to predict drug interchangeability. In addition, about 20,000 different types of genetic changes produced when drugs are administered to cells, as well as changes in physical condition after administration, are also reflected in AI. Researchers have shown that many diseases, such as cancer, diabetes, and Alzheimer's disease, are caused by certain specific proteins or genetic variations in the body. Therapeutic drugs inhibit the mutation by adhering to proteins, thereby alleviating the symptoms of the disease; It is not easy to figure out which drugs work for which proteins, and some drugs have some unknown effects, and hope to apply this innovation to the development of refractory and rare disease drugs. In general, it takes more than 10 years to develop a new drug and the cost of tens of billions to hundreds of billions of yen. Moreover, during the development process, it may be found that the drug has serious side effects, or it is difficult to achieve mass production, and thus cannot enter industrialization. This method is called "drug reposition", which uses other ingredients in existing drugs or drugs that have been previously developed to treat other diseases. In the past, relying mainly on the “accidental discovery†of the active ingredients, they now have a significant increase in efficiency through artificial intelligence and big data analytics. Researchers say that "AI drugs" help reduce development costs and increase development speed. I hope to improve the prediction accuracy through deep learning of AI, and strive to compress the new drug development cycle to less than 5 years. At present, researchers have joined the university hospitals and pharmaceutical companies to start a specific study on this new method of drug development, and have obtained some prediction results. Thread Lift,Medical Sharp Cannula Thread,Cosmetic Suture Thread,Disposable Thread Lift,PDO Material Thread Changzhou Timerein Biotechnology Co. , Ltd. , https://www.timereinbiotech.com